Simulations Plus
Market Cap
US$652.2m
Last Updated
2019/09/22 23:45 UTC
Data Sources
Company Financials +
Executive Summary
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide.
Snowflake
Fundamentals
Flawless balance sheet with reasonable growth potential.
Risks
- Simulations Plus has significant price volatility in the past 3 months.
- Simulations Plus is covered by less than 3 analysts.
Share Price & News
How has Simulations Plus's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
7.7%
SLP
1.6%
US Healthcare Services
-0.6%
US Market
1 Year Return
85.5%
SLP
9.9%
US Healthcare Services
0.7%
US Market
SLP outperformed the Healthcare Services industry which returned 10.2% over the past year.
SLP outperformed the Market in United States of America which returned 0.7% over the past year.
Share holder returns
| SLP | Industry | Market | |
|---|---|---|---|
| 7 Day | 7.7% | 1.6% | -0.6% |
| 30 Day | 3.8% | -0.06% | 4.9% |
| 90 Day | 30.4% | -1.4% | 1.7% |
| 1 Year | 87.5%85.5% | 10.0%9.9% | 3.0%0.7% |
| 3 Year | 350.8%332.1% | 52.6%52.2% | 44.8%35.4% |
| 5 Year | 506.8%451.1% | 51.7%50.8% | 62.0%44.3% |
Price Volatility Vs. Market
How volatile is Simulations Plus's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
Here's What Simulations Plus, Inc.'s (NASDAQ:SLP) P/E Is Telling Us2 weeks ago | Simply Wall St
Shareholders Are Raving About How The Simulations Plus (NASDAQ:SLP) Share Price Increased 435%1 month ago | Simply Wall St
What Kind Of Shareholders Own Simulations Plus, Inc. (NASDAQ:SLP)?Valuation
Is Simulations Plus undervalued based on future cash flows and its price relative to the stock market?
82.58x
Price to Earnings (PE) ratio
Intrinsic Value Based on Future Cash Flows
Simulations Plus's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
Simulations Plus's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
Price Based on Earnings
Simulations Plus is overvalued based on earnings compared to the US Healthcare Services industry average.
Simulations Plus is overvalued based on earnings compared to the United States of America market.
Price Based on Expected Growth
Simulations Plus is poor value based on expected growth next year.
Price Based on Value of Assets
Simulations Plus is overvalued based on assets compared to the US Healthcare Services industry average.
Next Steps
Future Growth
How is Simulations Plus expected to perform in the next 1 to 3 years based on estimates from 1 analyst?
31.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Simulations Plus's revenue is expected to grow by 15.2% yearly, however this is not considered high growth (20% yearly).
Simulations Plus's earnings are expected to grow significantly at over 20% yearly.
Simulations Plus's revenue growth is expected to exceed the United States of America market average.
Simulations Plus's earnings growth is expected to exceed the United States of America market average.
Simulations Plus's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Simulations Plus will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Simulations Plus performed over the past 5 years?
22.8%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Simulations Plus has delivered over 20% year on year earnings growth in the past 5 years.
Simulations Plus's 1-year earnings growth is negative, it can't be compared to the 5-year average.
Simulations Plus's 1-year earnings growth is negative, it can't be compared to the US Healthcare Services industry average.
Return on Equity
Simulations Plus has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
Return on Assets
Simulations Plus used its assets more efficiently than the US Healthcare Services industry average last year based on Return on Assets.
Return on Capital Employed
Simulations Plus's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Next Steps
Financial Health
How is Simulations Plus's financial position?
Financial Position Analysis
Simulations Plus is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Simulations Plus's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Simulations Plus has no debt.
Simulations Plus has not taken on any debt in the past 5 years.
Simulations Plus has no debt, it does not need to be covered by operating cash flow.
Simulations Plus has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Low level of unsold assets.
Simulations Plus has no debt, it does not need to be covered by short term assets.
Next Steps
Dividend
What is Simulations Plus's current dividend yield, its reliability and sustainability?
0.65%
Expected Dividend Yield
Dividend Yield and Payments Analysis
Simulations Plus's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).
Simulations Plus's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).
Simulations Plus is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.
Simulations Plus is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.
Current Payout to Shareholders
No need to calculate the sustainability of Simulations Plus's dividends as it is not paying a notable one for United States of America.
Future Payout to Shareholders
No need to calculate the sustainability of Simulations Plus's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of Simulations Plus's salary, the management and board of directors tenure and is there insider trading?
2.3yrs
Average management tenure
CEO
Shawn O'Connor (59yo)
1.3yrs
Tenure
US$618,419
Compensation
Mr. Shawn M. O'Connor has been Chief Executive Officer of Simulations Plus, Inc. since June 26, 2018. Mr. O'Connor served as Chief Executive Officer of Entelos, Inc. since July, 2011. Mr. O'Connor is a sea ...
CEO Compensation Analysis
Shawn's remuneration is lower than average for companies of similar size in United States of America.
Insufficient data for Shawn to compare compensation growth.
Management Age and Tenure
2.3yrs
Average Tenure
63yo
Average Age
The tenure for the Simulations Plus management team is about average.
Board Age and Tenure
4.8yrs
Average Tenure
71yo
Average Age
The tenure for the Simulations Plus board of directors is about average.
Insider Trading
Simulations Plus individual insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 690 |
| Max Price | US$37.86 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 3,000 |
| Max Price | US$22.74 |
Ownership Breakdown
Management Team
Walt Woltosz (74yo)
Co-Founder & Chairman
- Tenure: 23.2yrs
- Compensation: US$320.79k
Virginia Woltosz (68yo)
Co-Founder
- Tenure: 0yrs
- Compensation: US$60.00k
Shawn O'Connor (59yo)
Chief Executive Officer
- Tenure: 1.3yrs
- Compensation: US$618.42k
John DiBella (39yo)
President of the Lancaster Division
- Tenure: 2yrs
- Compensation: US$265.39k
Bob Clark
Senior Research Fellow
- Tenure: 9.7yrs
- Compensation: US$173.81k
Ted Grasela (65yo)
President of Cognigen Corporation
- Tenure: 0yrs
- Compensation: US$286.00k
John Kneisel (61yo)
Chief Financial Officer
- Tenure: 5.8yrs
- Compensation: US$222.73k
Brett Howell
President of DILIsym Services
- Tenure: 2.3yrs
Cynthia Walawander
Vice President of Operations
- Tenure: 0yrs
Board Members
Walt Woltosz (74yo)
Co-Founder & Chairman
- Tenure: 23.2yrs
- Compensation: US$320.79k
Dan Weiner (69yo)
Director
- Tenure: 2.3yrs
- Compensation: US$87.50k
Lisa LaVange
Independent Director
- Tenure: 0.3yrs
David Ralph (73yo)
Director
- Tenure: 7.5yrs
- Compensation: US$87.50k
John Paglia (52yo)
Director
- Tenure: 4.8yrs
- Compensation: US$93.50k
Company Information
Simulations Plus, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Simulations Plus, Inc.
- Ticker: SLP
- Exchange: NasdaqCM
- Founded: 1996
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: US$652.171m
- Shares outstanding: 17.53m
- Website: https://www.simulations-plus.com
Number of Employees
Location
- Simulations Plus, Inc.
- 42505 Tenth Street West
- Lancaster
- California
- 93534
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SLP | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jun 1997 |
| SD3 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 1997 |
Biography
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldw ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/22 23:45 |
| End of Day Share Price | 2019/09/20 00:00 |
| Earnings | 2019/05/31 |
| Annual Earnings | 2018/08/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.